Dr. Heather Wakelee and Dr. Julia Rotow dissect the clinical relevance of recent ASCO24 NSCLC studies. Their discussion highlights the findings from several trials including the EVOKE-01, CROWN, PALOMA-3 trials and more, focusing on how these findings can be integrated into clinical practice to optimize patient care and improve outcomes for patients with NSCLC.
Faculty
Julia Rotow, MD
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. USA
Heather Wakelee, MD, FASCO
Stanford University School of Medicine and Stanford Medicine, Stanford, CA. USA
Learning Objectives
After studying the program content, learners will be able to:
- Recall the latest data presented at ASCO 2024 on new therapeutic options for NSCLC.
- Evaluate the most recent clinical and real-world data behind therapeutic options in the neoadjuvant and adjuvant settings of NSCLC.
Target Audience
Practicing US-based specialist and community oncologists involved in the diagnosis and treatment of non-small cell lung carcinoma (NSCLC).
Accreditation
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
General Disclosures
In addition to the expert faculty, Postgraduate Institute for Medicine and Springer Healthcare IME planners and staff include Holly Keatts, Judith Mitchek, Maria Glukhovsky, Elizabeth Samander, and Jennifer Jett. The Planning Committee have no financial relationships to disclose.
All relevant financial relationships of the Faculty have been mitigated.
Funding Statement
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.